Comparative Pharmacology
Head-to-head clinical analysis: NEMBUTAL SODIUM versus PHRENILIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEMBUTAL SODIUM versus PHRENILIN.
NEMBUTAL SODIUM vs PHRENILIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Category C
Category C
Barbiturate
Barbiturate/Analgesic Combination